Karyopharm Therapeutics - KPTI Stock Forecast, Price & News

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Karyopharm Therapeutics in the last twelve months. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" KPTI shares.
View KPTI analyst ratings or view top-rated stocks.

7 Wall Street research analysts have issued 1 year price targets for Karyopharm Therapeutics' stock. Their KPTI share price forecasts range from $5.00 to $16.00. On average, they predict the company's stock price to reach $9.50 in the next twelve months. This suggests a possible upside of 144.2% from the stock's current price.
View analysts price targets for KPTI or view top-rated stocks among Wall Street analysts.

Karyopharm Therapeutics' stock was trading at $3.40 on January 1st, 2023. Since then, KPTI stock has increased by 14.4% and is now trading at $3.89.
View the best growth stocks for 2023 here.

Karyopharm Therapeutics saw a drop in short interest during the month of March. As of March 15th, there was short interest totaling 16,730,000 shares, a drop of 8.7% from the February 28th total of 18,330,000 shares. Based on an average daily trading volume, of 2,760,000 shares, the short-interest ratio is presently 6.1 days.
View Karyopharm Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our KPTI earnings forecast.

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) announced its earnings results on Wednesday, February, 15th. The company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.34) by $0.09. The company had revenue of $33.58 million for the quarter, compared to the consensus estimate of $33.88 million.

ETFs with the largest weight of Karyopharm Therapeutics (NASDAQ:KPTI) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Invesco Nasdaq Future Gen 200 ETF (QQQS) and iShares Biotechnology ETF (IBB).

Karyopharm Therapeutics updated its FY 2023 earnings guidance on Wednesday, February, 15th. The company provided EPS guidance of for the period. The company issued revenue guidance of $160.00 million-$175.00 million, compared to the consensus revenue estimate of $163.24 million.

31 employees have rated Karyopharm Therapeutics Chief Executive Officer Michael Kauffman on Glassdoor.com. Michael Kauffman has an approval rating of 83% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Karyopharm Therapeutics investors own include NVIDIA (NVDA), Gilead Sciences (GILD), CRISPR Therapeutics (CRSP), Alibaba Group (BABA), Micron Technology (MU), Invitae (NVTA), Advanced Micro Devices (AMD), AbbVie (ABBV), Inovio Pharmaceuticals (INO) and Bristol-Myers Squibb (BMY).

Karyopharm Therapeutics trades on the NASDAQ under the ticker symbol "KPTI."

Shares of KPTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of KPTI stock can currently be purchased for approximately $3.89.

Karyopharm Therapeutics (NASDAQ:KPTI) has a market capitalization of $440.89 million and generates $157.07 million in revenue each year. The company earns $-165,290,000.00 in net income (profit) each year or ($2.03) on an earnings per share basis.

The company employs 442 workers across the globe.

Karyopharm Therapeutics' mailing address is 85 WELLS AVENUE SECOND FLOOR, NEWTON MA, 02459. The official website for the company is www.karyopharm.com. The company can be reached via phone at (617) 658-0600 or via email at ikarp@karyopharm.com.